WM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
WM is not a good buy right now for an impatient buyer. The stock is trading below its pivot (225.81) with weakening momentum (MACD histogram negative and expanding), and the pattern-based odds skew negative over the next week/month. While fundamentals and analyst targets remain supportive, near-term technicals plus heavy insider selling argue against chasing today; I would hold (or wait for a reclaim of ~226+ or a cleaner bounce off ~220 support before buying).
Price/levels: WM closed near 222, below the Pivot at 225.809. Immediate support sits at S1 220.233 (then S2 216.789). Overhead resistance is R1 231.384 (then R2 234.828).
Momentum: MACD histogram is -0.0331 and negatively expanding, which signals bearish momentum is still building rather than stabilizing.
RSI: RSI(6) 36.3, approaching oversold-ish territory but not yet a strong reversal signal; this can precede a bounce, but it can also stay weak during a drift lower.
Moving averages: Converging MAs suggest consolidation, but with price below pivot and MACD deteriorating, the consolidation currently tilts bearish.
Near-term path: With price sitting just above S1 (220), the technical setup looks like a "weak trend near support"—tradable for a bounce only if support holds, but not a clean buy-now trend.
Intellectia Proprietary Trading Signals
Q4 2025 operating cash flow grew >12% to ~$6.04B, signaling strong cash generation.
Dividend increased ~14.5% for 2026 (shareholder return tailwind).
Analyst commentary highlights better-than-expected margin performance and improving unit profitability (pricing ahead of inflation).
Multiple firms reiterate Buy/Overweight with targets commonly in the $250–$265 range (supports downside perception).
Q4 EPS and revenue slightly missed expectations, and the stock reacted negatively around results.
Technical momentum is weakening (bearish MACD expansion) with price below key pivot.
Insider activity: insiders are selling, with selling amount up sharply over the last month (bearish signal on near-term confidence).
Pattern-based outlook provided: expected drift lower over the next week/month (approx. -2.41% next week, -5.34% next month).
Hedge funds are reported as neutral (no strong institutional accumulation signal).
Latest quarter: 2025/Q4. Revenue was $6.313B, +7.13% YoY (steady top-line growth). Profitability improved materially: net income $742M, +24.08% YoY; EPS $1.83, +23.65% YoY. Gross margin rose to 29.3% (+2.30% YoY), indicating operating leverage/pricing strength despite the headline revenue/EPS miss versus estimates.
Recent trend: Price targets are generally being raised/maintained at elevated levels (many clustered around $250–$265). UBS upgraded to Buy with a $260 target; Wells Fargo reiterated Overweight and raised to $250; Jefferies maintained Buy at $250; Barclays and Citi stayed constructive. One notable negative: Scotiabank downgraded to Sector Perform mainly on relative performance/valuation after outperformance. Wall Street pros: strong free cash flow, dividend/repurchase support, pricing power and margin improvement. Wall Street cons: valuation after outperformance, tougher comps, and investor scrutiny around guidance/EBITDA calculation changes; near-term execution expectations are high after the run.
